This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Yoshida, T. Articles by Homma, M. Search for Related Content PubMed PubMed Citation Articles by Yoshida, T. Articles by Homma, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Lupus Social Bookmarking                   What's this?

Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904

Department of Internal Medicine, School of Medicine, Keio University

Y. Ichikawa

Department of Internal Medicine and St. Marianna University School of Medicine

T. Tojo

Department of Internal Medicine, School of Medicine, Keio University

M. Homma

Department of Internal Medicine, School of Medicine, Keio University

Abnormalities of prostanoid metabolism, which may affect renal function, were studied in lupus nephritis. The subjects were 31 patients with lupus nephritis, ten with non-renal SLE, and four with renal, non-SLE collagen disease. Urinary levels of various prostanoids, thromboxane B₂(TXB₂), 11-dehydro-TXB ₂, 6-keto-PGF1,2,3-dinor-6-keto-PGF1 and PGE₂, and plasma level of 11-dehydro-TXB₂ were determined. The effects of four days' dosing of a selective thromboxane A₂ (TXA₂ ) synthetase inhibitor, DP-1904 (DP), on pros tanoid metabolism, were also studied.

Urinary excretion of TXB ₂, which reflects the renal production of TXA₂, was signifi cantly increased in the patients with lupus nephritis as compared with non-renal SLE (p < 0.05). The urinary TXB₂/6-keto-PGF1 ratio was also increased in lupus nephritis as compared with non-renal SLE or healthy controls (p < 0.01), indicating a prostanoid imbal ance, which may lead to impaired renal function and subsequent pathology. The urinary TXB₂/6-keto-PGF₁ ratio in these lupus nephritis patients showed negative correlations with Ccr and positive correlations with anti-DNA antibody titer (p < 0.001).

DP was administered orally (400 mg/day, given in two divided doses) for four days to eight lupus nephritis patients. The urinary excretion of TXB₂ and urinary TXB₂/6-keto- PGF1 ratio were decreased after one to two days of treatment in all patients. An increase in creatinine clearance used as a measure of renal function was observed in four of eight patients. Furthermore, no side effects were elicited during the four days of treatment.

The conclusions reached were that the abnormal prostanoid metabolism observed in lupus nephritis could aggravate renal function through hemodynamic mediation, and that the deviated metabolism was reversible and, at least partially, corrected by a TXA₂ syn thetase inhibitor.

Key Words: lupus nephritis • prostanoids • thromboxane A2 • prostacyclin • thromboxane A2 synthetase inhibitor

Lupus, Vol. 5, No. 2, 129-138 (1996)
DOI: 10.1177/096120339600500208


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. Avalos, C. P. Chung, A. Oeser, G. L. Milne, H. Borntrager, J. D. Morrow, P. Raggi, J. Solus, and C. M. Stein Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus Lupus, December 1, 2007; 16(12): 981 - 986. [Abstract] [PDF]

				M ostensen and P M Villiger Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus Lupus, October 1, 2000; 9(8): 566 - 572. [Abstract] [PDF]

				G G Illei and J H Klippel Novel approaches in the treatment of lupus nephritis Lupus, November 1, 1998; 7(9): 644 - 648. [Abstract] [PDF]

				M. Nakano, M. Ueno, H. Hasegawa, T. Watanabe, T. Kuroda, S. Ito, and M. Arakawa Renal haemodynamic characteristics in patients with lupus nephritis Ann Rheum Dis, April 1, 1998; 57(4): 226 - 230. [Abstract] [Full Text]